BACKGROUND:Anxiety, depression, and impaired health-related quality of life (HRQoL) are common in patients with psoriasis. OBJECTIVE: We sought to analyze the effect of ustekinumab on these conditions in patients with moderate-to-severe psoriasis. METHODS:Patients with moderate-to-severe psoriasis (n = 1230) were randomized 1:1:1 to receive 45 mg of ustekinumab, 90 mg of ustekinumab, or placebo. The Hospital Anxiety and Depression Scale was used to measure anxiety and depression, and the Dermatology Life Quality Index to measure HRQoL. RESULTS: At baseline, 40.3% and 26.7% of patients reported symptoms of anxiety and depression, respectively, and 54.6% reported Dermatology Life Quality Index scores greater than 10, indicating a very high impact of disease on HRQoL. Greater improvements at week 12 in mean Hospital Anxiety and Depression Scale-Anxiety (13.9%), Hospital Anxiety and Depression Scale-Depression (29.3%), and Dermatology Life Quality Index (76.2%) scores were reported in ustekinumab groups compared with placebo (P < .001 each). LIMITATIONS: Results for these measures are reported only through 24 weeks. CONCLUSION: Patients receiving ustekinumab reported significant improvements in symptoms of anxiety, depression, and HRQoL. Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND:Anxiety, depression, and impaired health-related quality of life (HRQoL) are common in patients with psoriasis. OBJECTIVE: We sought to analyze the effect of ustekinumab on these conditions in patients with moderate-to-severe psoriasis. METHODS:Patients with moderate-to-severe psoriasis (n = 1230) were randomized 1:1:1 to receive 45 mg of ustekinumab, 90 mg of ustekinumab, or placebo. The Hospital Anxiety and Depression Scale was used to measure anxiety and depression, and the Dermatology Life Quality Index to measure HRQoL. RESULTS: At baseline, 40.3% and 26.7% of patients reported symptoms of anxiety and depression, respectively, and 54.6% reported Dermatology Life Quality Index scores greater than 10, indicating a very high impact of disease on HRQoL. Greater improvements at week 12 in mean Hospital Anxiety and Depression Scale-Anxiety (13.9%), Hospital Anxiety and Depression Scale-Depression (29.3%), and Dermatology Life Quality Index (76.2%) scores were reported in ustekinumab groups compared with placebo (P < .001 each). LIMITATIONS: Results for these measures are reported only through 24 weeks. CONCLUSION:Patients receiving ustekinumab reported significant improvements in symptoms of anxiety, depression, and HRQoL. Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Authors: Shariful A Syed; Eléonore Beurel; David A Loewenstein; Jeffrey A Lowell; W Edward Craighead; Boadie W Dunlop; Helen S Mayberg; Firdaus Dhabhar; W Dalton Dietrich; Robert W Keane; Juan Pablo de Rivero Vaccari; Charles B Nemeroff Journal: Neuron Date: 2018-08-23 Impact factor: 17.173
Authors: Richard G B Langley; Kristian Reich; Vibeke Strand; Steven R Feldman; Carle Paul; Kenneth Gordon; Richard B Warren; Darryl Toth; Enkeleida Nikaï; Baojin Zhu; Orin Goldblum; Emily Edson-Heredia; Hilde Carlier; Russel Burge; Chen-Yen Lin; Kristin Hollister; Matthias Augustin Journal: Qual Life Res Date: 2019-10-26 Impact factor: 4.147